Company / Financials
TherapeuticsMD, Inc. Financials
FY2011-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableRevenue
$1.3M
FY2024 · -98.1% YoY
Net Income
-$10.3M
FY2024 · -109.2% YoY
Profit Margin
-789.4%
FY2024 · net income / revenue
ROE
-35.1%
FY2024 · return on equity
Total Assets
$38.8M
FY2024
Total Debt
-
FY2024
Equity
$29.3M
FY2024
ROA
-26.5%
FY2024 · return on assets
Statement paths
Financial highlights
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 0.77 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Metric history
Revenue HistoryTotal revenue from operations$1.3M-98.1% YoYNet Income HistoryProfit after all expenses and taxes-$10.3M-109.2% YoYGross Profit HistoryRevenue minus cost of goods sold-Cost of Revenue HistoryDirect costs of producing goods and services sold-Operating Income HistoryProfit from core business operations before interest and taxes-$8.5M-815.6% YoYSG&A Expense HistorySelling, general, and administrative expenses$8.9M-84.3% YoYR&D Expense HistoryResearch and development spending-Interest Expense HistoryCost of borrowing and debt obligations$166.6K-16.7% YoYIncome Tax HistoryTotal income tax expense-$43.0K0.0% YoYEPS (Basic) HistoryBasic earnings per share-$0.99-108.0% YoY